WaferGen completes $30.6mm private placement
Executive Summary
WaferGen Biosystems Inc. (genomic analysis tools) has closed a $30.6mm private placement of equity and debt (issuing 2.9mm Series A-1 convertible shares, $15.275mm in promissory notes, and warrants redeemable for 56mm common shares) to Great Point Partners, Deerfield Management, Merlin Nexus, Shivji Family Trust, CIBC Trust Co., Kanter Family Foundation, Biomedical Value Fund, Biomedical Institutional Value Fund, Biomedical Offshore Value Fund, WS Investments III, Lyrical Multi-Manager Fund, Deerfield Special Situation Fund, and Deerfield Private Design Fund; certain management personnel and board members--including Robert Coradini, David Morrison, Jeffrey Jay, Paul Schimmel, and Joel Kanter--participated as well. Placement agents were Oppenheimer & Co. (lead), Madison Williams & Co., and Summer Street Research Partners.
Deal Industry
- Research, Analytical Equipment & Supplies
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Other
- Private Investment in Public Equity
- Private Placement
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice